AV-101: Phase I data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 46 healthy volunteers showed that once-daily 360, 1,080 and 1,440 mg doses of oral AV-101 for 14 days were well tolerated wit...